Condensed Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Common stock	Treasury stock	Additional paid-in capital	Accumulated deficit
Beginning balance common stock, shares, outstanding (in shares) at Dec. 31, 2022		51,526,100
Beginning balance at Dec. 31, 2022	$ 68,747	$ 5	$ (8)	$ 800,768	$ (732,018)
Beginning balance treasury stock, shares (in shares) at Dec. 31, 2022			(26,666)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Public offering	(1)			(1)
Exercise of common stock options (in shares)		3,008
Exercise of common stock options	1			1
Restricted stock units vested (in shares)		156,855
Restricted stock units vested	0
Stock-based compensation	3,836			3,836
Net income (loss)	(27,595)				(27,595)
Ending balance common stock, shares, outstanding (in shares) at Mar. 31, 2023		51,685,963
Ending balance at Mar. 31, 2023	44,988	$ 5	$ (8)	804,604	(759,613)
Ending balance treasury stock, shares (in shares) at Mar. 31, 2023			(26,666)
Beginning balance common stock, shares, outstanding (in shares) at Dec. 31, 2022		51,526,100
Beginning balance at Dec. 31, 2022	68,747	$ 5	$ (8)	800,768	(732,018)
Beginning balance treasury stock, shares (in shares) at Dec. 31, 2022			(26,666)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(18,885)
Ending balance common stock, shares, outstanding (in shares) at Jun. 30, 2023		51,735,113
Ending balance at Jun. 30, 2023	57,548	$ 5	$ (8)	808,454	(750,903)
Ending balance treasury stock, shares (in shares) at Jun. 30, 2023			(26,666)
Beginning balance common stock, shares, outstanding (in shares) at Mar. 31, 2023		51,685,963
Beginning balance at Mar. 31, 2023	44,988	$ 5	$ (8)	804,604	(759,613)
Beginning balance treasury stock, shares (in shares) at Mar. 31, 2023			(26,666)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Public offering	40			40
Exercise of common stock options	0
Restricted stock units vested (in shares)		49,150
Restricted stock units vested	0
Stock-based compensation	3,810			3,810
Net income (loss)	8,710				8,710
Ending balance common stock, shares, outstanding (in shares) at Jun. 30, 2023		51,735,113
Ending balance at Jun. 30, 2023	$ 57,548	$ 5	$ (8)	808,454	(750,903)
Ending balance treasury stock, shares (in shares) at Jun. 30, 2023			(26,666)
Beginning balance common stock, shares, outstanding (in shares) at Dec. 31, 2023	51,926,075	51,952,741
Beginning balance at Dec. 31, 2023	$ 35,386	$ 5	$ (8)	815,374	(779,985)
Beginning balance treasury stock, shares (in shares) at Dec. 31, 2023	(26,666)		(26,666)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Public offering	$ 0
Exercise of common stock options (in shares)		90,266
Exercise of common stock options	26			26
Restricted stock units vested (in shares)		218,044
Restricted stock units vested	0
Stock-based compensation	2,546			2,546
Net income (loss)	(10,219)				(10,219)
Ending balance common stock, shares, outstanding (in shares) at Mar. 31, 2024		52,261,051
Ending balance at Mar. 31, 2024	$ 27,739	$ 5	$ (8)	817,946	(790,204)
Ending balance treasury stock, shares (in shares) at Mar. 31, 2024			(26,666)
Beginning balance common stock, shares, outstanding (in shares) at Dec. 31, 2023	51,926,075	51,952,741
Beginning balance at Dec. 31, 2023	$ 35,386	$ 5	$ (8)	815,374	(779,985)
Beginning balance treasury stock, shares (in shares) at Dec. 31, 2023	(26,666)		(26,666)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock options (in shares)	179,835
Net income (loss)	$ (15,688)
Ending balance common stock, shares, outstanding (in shares) at Jun. 30, 2024	52,697,879	52,724,545
Ending balance at Jun. 30, 2024	$ 24,592	$ 5	$ (8)	820,268	(795,673)
Ending balance treasury stock, shares (in shares) at Jun. 30, 2024	(26,666)		(26,666)
Beginning balance common stock, shares, outstanding (in shares) at Mar. 31, 2024		52,261,051
Beginning balance at Mar. 31, 2024	$ 27,739	$ 5	$ (8)	817,946	(790,204)
Beginning balance treasury stock, shares (in shares) at Mar. 31, 2024			(26,666)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Public offering	0
Exercise of common stock options (in shares)		89,569
Exercise of common stock options	232			232
Restricted stock units vested (in shares)		373,925
Restricted stock units vested	0
Stock-based compensation	2,090			2,090
Net income (loss)	$ (5,469)				(5,469)
Ending balance common stock, shares, outstanding (in shares) at Jun. 30, 2024	52,697,879	52,724,545
Ending balance at Jun. 30, 2024	$ 24,592	$ 5	$ (8)	$ 820,268	$ (795,673)
Ending balance treasury stock, shares (in shares) at Jun. 30, 2024	(26,666)		(26,666)

G1 Therapeutics, Inc. 10-Q